rac-3-[(4-(2-Methoxymethylpiperidin-1-yl)-1,3,5-triazin-2-yl)amino]-benzenemethanesulfonamide → (R)-3-[(4-(2-Methoxymethylpiperidin-1-yl)-1,3,5-triazin-2-yl)amino]-benzenemethanesulfonamide

참여 물질

반응 단계

B5 was prepared following the procedure reported for B4 using the intermediates A1 and A2 and obtained as a white crystalline solid; yield: 90 mg (25%). 1H NMR (300 MHz, d6-DMSO, 300K) δ 1.27-1.90 (m, 4H), 2.48-2.60 (m, 2H), 2.90-3.03 (m, 1H), 3.38 (s, 3H), 3.61 (bs, 2H), 4.26 (s, 2H), 4.61-4.75 (m, 1H), 5.03-5.15 (m, 1H), 6.90 (bs, 2H), 7.03-7.10 (m, 1H), 7.28-7.40 (m, 1H), 7.62-7.73 (m, 1H), 7.82 (bs, 1H), 8.28 (s, 1H), 9.68 (bs, 1H). MS (ES) C17H24N6O3S requires: 392. found: 393 (M+H)+.

출처 및 근거